Sanofi (SNY): price, analyst ratings, earnings and fundamentals
Updated 16 September 2026, 08:02 ET
Sanofi (SNY) closed at $42.40 on 15 September 2026, down 2.1%. The stock is down 3.0% over one month and down 9.8% over one year. It trades 19.5% below its 52-week high of $52.68. The company last reported on 30 July 2026 for Q2 2026: EPS of $1.21 against an estimate of $1.09, a beat of 11.4%, on revenue of $13.5 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open SNY in FundSpec.
Analyst ratings
No analyst action on SNY was recorded in the last 90 days; the most recent is from 16 January 2026.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 16 Jan 2026 | UBS | Downgrades to Neutral from Buy | |
| 6 Jan 2026 | Barclays | Downgrades to Equal-Weight from Overweight | |
| 9 Dec 2025 | Guggenheim | Downgrades to Neutral from Buy | |
| 8 Dec 2025 | JP Morgan | Downgrades to Neutral from Overweight | |
| 27 Oct 2025 | Jefferies | Assumes Buy | |
| 8 Sep 2025 | Morgan Stanley | Upgrades to Overweight from Equal-Weight | $56.00 to $58.00 |
| 2 Sep 2025 | Deutsche Bank | Upgrades to Buy from Hold | |
| 8 Aug 2025 | JP Morgan | Upgrades to Overweight from Neutral | |
| 21 Mar 2025 | Goldman Sachs | Initiates Coverage On Neutral | $65.00 |
| 26 Jul 2024 | Argus Research | Maintains Buy | $55.00 to $60.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 30 October 2026 before the open for Q3 2026, with EPS expected at $1.72 on revenue of $15.3 billion. Sanofi beat the EPS estimate in 5 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 30 Jul 2026 | $1.09 | $1.21 | +11.38% | $13.5B |
| Q1 2026 | 23 Apr 2026 | $1.06 | $1.10 | +3.77% | $12.3B |
| Q4 2025 | 29 Jan 2026 | $0.84 | $0.89 | +5.95% | $13.2B |
| Q3 2025 | 24 Oct 2025 | $1.60 | $1.70 | +6.31% | $14.5B |
| Q2 2025 | 31 Jul 2025 | $0.96 | $0.90 | -6.15% | $11.3B |
| Q1 2025 | 24 Apr 2025 | $0.95 | $0.94 | -0.95% | $10.4B |
| Q4 2024 | 30 Jan 2025 | $0.74 | $0.70 | -5.41% | $11.3B |
| Q3 2024 | 25 Oct 2024 | $1.39 | $1.57 | +12.95% | $14.8B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
On a trailing twelve month basis the company shows revenue growth of N.A., a gross margin of N.A., an operating margin of N.A. and a return on equity of 10.55%.
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $7,657,000,000 |
| Inventory | $10,214,000,000 |
| Other Current Assets | $4,066,000,000 |
| Total Current Assets | $30,952,000,000 |
| Plant, Property & Equipment, Net | $10,052,000,000 |
| Goodwill Intangible Assets, Net | $67,561,000,000 |
| Deferred Tax Asset | $8,608,000,000 |
| Total Assets | $126,805,000,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Total Short-term Debt | $4,342,000,000 |
| Other Current Liabilities | $11,902,000,000 |
| Total Current Liabilities | $28,345,000,000 |
| Long-term Debt | $18,702,000,000 |
| Minority Interest | $334,000,000 |
| Other Liabilities | $2,162,000,000 |
| Total Liabilities | $55,095,000,000 |
| Total Stockholders Equity | $71,376,000,000 |
| Total Liability & Stockholders Equity | $126,805,000,000 |
Figures as filed with the SEC for the period ended 31 December 2025, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 0.27 | 50th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 1.09 | 48th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.18 | 64th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.32 | 55th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Financial Leverage | 1.10 | 66th | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
| Long Term Debt/Long Term Capital | 0.21 | 31st | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
| Long Term Debt/Total Capital | 0.20 | 31st | Calculated as (Short-Term Debt + Long-Term Debt / (Short-Term Debt + Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | -12.5% | 71st | The EBIT growth rate over the trailing twelve months (TTM) |
| EBIT Pct Growth 3 year CAGR | -14.5% | 98th | The EBIT compound annual growth rate (CAGR) over the past 3 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 39.7% | 68th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | -2.6% | 41st | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | -8.6% | 31st | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Cashflow Pct Growth | 18.4% | 59th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 0.7% | 43rd | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 7.7% | 62nd | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Profit Pct Growth | -12.5% | 33rd | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | -14.5% | 27th | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | -14.8% | 25th | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| Return on Assets Pct | 6.0% | 83rd | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 10.5% | 68th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 5.7% | 59th | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 11.7% | 54th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open SNY in FundSpec.
Insider activity
In the last 90 days insiders filed 7 transactions: 4 acquisitions covering 1,755,633 shares and 3 disposals covering 1,455,633 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was an acquisition of 300,000 shares by Sanofi, 10% Owner on 6 August 2026, worth about $5.1 million at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10 Aug 2026 | Sanofi | 10% Owner | Disposal | 177,978 | ||
| 10 Aug 2026 | Sanofi | 10% Owner | Acquisition | 494,800 | ||
| 10 Aug 2026 | Sanofi | 10% Owner | Disposal | 494,800 | ||
| 10 Aug 2026 | Sanofi | 10% Owner | Acquisition | 177,978 | ||
| 6 Aug 2026 | Sanofi | 10% Owner | Acquisition | 300,000 | $17.00 | $5.1M |
| 6 Aug 2026 | Sanofi | 10% Owner | Acquisition | 782,855 | ||
| 6 Aug 2026 | Sanofi | 10% Owner | Disposal | 782,855 | ||
| 14 Sep 2021 | Sanofi | 10% Owner | Acquisition | 51,467,612 | $38.00 | $2.0B |
| 14 Sep 2021 | Sanofi | 10% Owner | Acquisition | 20,515,985 | $38.00 | $779.6M |
| 2 Aug 2021 | Sanofi | 10% Owner | Acquisition | 66,667 | $15.00 | $1.0M |
| 2 Aug 2021 | Sanofi | 10% Owner | Acquisition | 3,088,502 | ||
| 2 Aug 2021 | Sanofi | 10% Owner | Disposal | 354,393 | ||
| 2 Aug 2021 | Sanofi | 10% Owner | Disposal | 12,480,498 | ||
| 28 Jul 2020 | Sanofi | 10% Owner | Acquisition | 81,250 | $16.00 | $1.3M |
| 28 Jul 2020 | Sanofi | 10% Owner | Acquisition | 438,875 |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 20-F from 17 February 2026.
| Filed | Form | Document |
|---|---|---|
| 17 Feb 2026 | 20-F | View on sec.gov |
| 13 Feb 2025 | 20-F | View on sec.gov |
| 23 Feb 2024 | 20-F | View on sec.gov |
| 24 Feb 2023 | 20-F | View on sec.gov |
| 23 Feb 2022 | 20-F | View on sec.gov |
| 4 Mar 2021 | 20-F | View on sec.gov |
| 5 Mar 2020 | 20-F | View on sec.gov |
| 8 Mar 2019 | 20-F | View on sec.gov |
| 16 Mar 2018 | 20-F/A | View on sec.gov |
| 7 Mar 2018 | 20-F | View on sec.gov |
Company profile
- Exchange
- Nasdaq
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Headquarters
- Paris, France
- Chief executive
- Paul Hudson
- Employees
- 91,600
- Website
- sanofi.com
- SEC CIK
- 0001121404
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation.
Sector and peers
Sanofi is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 614 companies.
Companies in the same industry by market capitalization:
PG PROCTER & GAMBLE CoNVO Novo Nordisk A SUL Unilever plcGSK GSK plcECL Ecolab Inc.ARGX Argenx SeTAK Takeda Pharmaceutical Co. Ltd.HLN Haleon plc
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for SNY are available to subscribers, with the same screen in the iOS and Android apps.
Open SNY in FundSpec